litlas
Log inCreate account

Tae Won Kim

Active 1991–2026

Also published as
Tae‐Won Kim · Tae-Won Kim · Tae-won Kim
192
Papers
23,189
Citations
75
h-index
162
i10-index

Citations

Citations per year for Tae Won Kim1979: 1 citations1991: 2 citations1992: 1 citations1993: 1 citations1994: 2 citations1996: 3 citations1998: 2 citations1999: 3 citations2001: 2 citations2002: 6 citations2003: 2 citations2004: 14 citations2005: 12 citations2006: 17 citations2007: 18 citations2008: 32 citations2009: 29 citations2010: 40 citations2011: 39 citations2012: 50 citations2013: 47 citations2014: 51 citations2015: 80 citations2016: 96 citations2017: 111 citations2018: 122 citations2019: 424 citations2020: 754 citations2021: 1,261 citations2022: 1,157 citations2023: 1,032 citations2024: 1,714 citations2025: 946 citations2026: 42 citations1980–1990: no citations, so these years are not shown1995: no citations, so this year is not shown1997: no citations, so this year is not shown2000: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,196 citing papers, 21.5% of this breakdownChina: 1,484 citing papers, 14.5% of this breakdownItaly: 640 citing papers, 6.3% of this breakdownUnited Kingdom: 533 citing papers, 5.2% of this breakdownGermany: 467 citing papers, 4.6% of this breakdownFrance: 466 citing papers, 4.5% of this breakdownJapan: 412 citing papers, 4% of this breakdownSouth Korea: 373 citing papers, 3.6% of this breakdownSpain: 367 citing papers, 3.6% of this breakdownNetherlands: 298 citing papers, 2.9% of this breakdownCanada: 248 citing papers, 2.4% of this breakdownAustralia: 241 citing papers, 2.4% of this breakdown
0%21.5%Other 24.5%

Institutions

Fields

  • Medicine62.7%
  • Biochemistry, Genetics and Molecular Biology20.9%
  • Neuroscience3.5%
  • Immunology and Microbiology3.1%
  • Computer Science2.3%
  • Engineering2%
  • Other5.5%

Topics

  • Colorectal Cancer Treatments and Studies7.9%
  • Cancer Immunotherapy and Biomarkers7.3%
  • Genetic factors in colorectal cancer4.2%
  • Cancer Genomics and Diagnostics3.6%
  • Lung Cancer Treatments and Mutations2.6%
  • Colorectal Cancer Surgical Treatments2.5%
  • Other71.9%

Coauthors

All papers

Open in search
  1. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

    Authors: Thierry André, Kai‐Keen Shiu, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J.A. Punt, Denis Smith, Rocio García‐Carbonero, Manuel Benavides, Peter Gibbs, Christelle de la Fouchardière, Fernando Rivera, Elena Élez, Johanna C. Bendell, Dung T. Le, Takayuki Yoshino, Eric Van Cutsem, Ping Yang, Mohammed Z.H. Farooqui, Patricia Marinello, Luis A. Díaz - New England Journal of Medicine 2020 cited by 2,954

  2. KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

    Authors: David S. Hong, Marwan Fakih, John H. Strickler, Jayesh Desai, Gregory A. Durm, Geoffrey I. Shapiro, Gerald S. Falchook, Timothy Price, Adrian G. Sacher, Crystal S. Denlinger, Yung‐Jue Bang, Grace K. Dy, John C. Krauss, Yasutoshi Kuboki, James Kuo, Andrew L. Coveler, Keunchil Park, Tae Won Kim, Fabrice Barlési, Pamela N. Münster, Suresh S. Ramalingam, Timothy F. Burns, Funda Meric‐Bernstam, Haby Henary, Jude Ngang, Gataree Ngarmchamnanrith, June Myung Kim, Brett E. Houk, Jude Canon, J. Russell Lipford, Gregory Friberg, Piro Lito, Ramaswamy Govindan, Bob T. Li - New England Journal of Medicine 2020 cited by 1,687

  3. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

    Authors: Luis A. Díaz, Kai‐Keen Shiu, Tae‐Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J.A. Punt, Denis Smith, Rocio García‐Carbonero, Manuel Benavides, Peter Gibbs, Christelle de la Fourchardière, Fernando Rivera, Elena Élez, Dung T. Le, Takayuki Yoshino, Wen Yan Zhong, David R. Fogelman, Patricia Marinello, Thierry André - The Lancet Oncology 2022 cited by 894

  4. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

    Authors: Scott Kopetz, Axel Grothey, Rona Yaeger, Eric Van Cutsem, Jayesh Desai, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Fotios Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Kyrre Guren, Hendrik‐Tobias Arkenau, Pilar García‐Alfonso, Per Pfeiffer, Sergey Orlov, Sara Lonardi, Elena Élez, Tae-Won Kim, Jan H.M. Schellens, Christina Guo, Asha Krishnan, Jeroen Dekervel, Van K. Morris, Aitana Calvo Ferrandiz, Line Schmidt Tarpgaard, Michael Braun, Ashwin Gollerkeri, Christopher Hunt Keir, Kati Maharry, Michael D. Pickard, Janna Christy‐Bittel, Lisa Anderson, Victor Sandor, Josep Tabernero - New England Journal of Medicine 2019 cited by 1,465

  5. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

    Authors: Adrian G. Sacher, Patricia LoRusso, Manish R. Patel, Wilson H. Miller, Elena Garralda, Martin Förster, Armando Santoro, Alejandro Falcón, Tae Won Kim, Luis Paz‐Ares, Samantha Bowyer, Maria de Miguel, Sae‐Won Han, Matthew Krebs, Jong Seok Lee, Michael L. Cheng, Kathryn C. Arbour, Erminia Massarelli, Yoonha Choi, Zhen Shi, Sandhya Mandlekar, Mark T. Lin, Stephanie Royer‐Joo, Julie Chang, Neekesh V. Dharia, Jennifer L. Schutzman, Jayesh Desai - New England Journal of Medicine 2023 cited by 294

  6. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C

    Authors: Marwan Fakih, Lisa Salvatore, Taito Esaki, Dominik Paul Modest, D. Páez López-Bravo, Julien Taı̈eb, Michalis V. Karamouzis, Erika Ruíz‐García, Tae‐Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun‐Huei Yeh, Emily Chan, Joseph Chao, Yaneth Saportas, Qui Tran, Chiara Cremolini, Filippo Pietrantonio - New England Journal of Medicine 2023 cited by 342

  7. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

    Authors: Dung T. Le, Tae Won Kim, Eric Van Cutsem, Ravit Geva, Dirk Jäger, Hiroki Hara, Matthew Burge, Bert H. O’Neil, Petr Kavan, Takayuki Yoshino, Rosine Guimbaud, Hiroya Taniguchi, Elena Élez, Salah‐Eddin Al‐Batran, Patrick M. Boland, Todd S. Crocenzi, Chloé E. Atreya, Yi Cui, Tong Dai, Patricia Marinello, Luis A. Díaz, Thierry André - Journal of Clinical Oncology 2019 cited by 1,014

  8. Neural network analysis of sleep stages enables efficient diagnosis of narcolepsy

    Authors: Jens B. Stephansen, A N Olesen, Mads Olsen, Aditya Ambati, Eileen Leary, Hyatt Moore, Oscar Carrillo, Ling Lin, Fang Han, Han Yan, Yun L. Sun, Yves Dauvilliers, Sabine Scholz, Lucie Barateau, Birgit Högl, Ambra Stefani, Seung Chul Hong, Tae Won Kim, Fabio Pizza, Giuseppe Plazzi, Stefano Vandi, Elena Antelmi, Dimitri Perrin, Samuel T. Kuna, Paula K. Schweitzer, Clete A. Kushida, Paul E. Peppard, Helge B. D. Sørensen, Poul Jennum, Emmanuel Mignot - Nature Communications 2018 cited by 398

  9. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial

    Authors: Marwan G Fakih, Scott Kopetz, Yasutoshi Kuboki, Tae Won Kim, Pamela N Munster, John C Krauss, Gerald S Falchook, Sae-Won Han, Volker Heinemann, Kei Muro, John H Strickler, David S Hong, Crystal S Denlinger, Gustavo Girotto, Myung-Ah Lee, Haby Henary, Qui Tran, Joseph K Park, Gataree Ngarmchamnanrith, Hans Prenen, Timothy J Price - The Lancet Oncology 2021 cited by 288

  10. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

    Authors: Cathy Eng, Tae Won Kim, Johanna C. Bendell, Guillem Argilés, Niall C. Tebbutt, Maria Di Bartolomeo, Alfredo Falcone, Marwan Fakih, Mark Kozloff, Neil H. Segal, Alberto Sobrero, Yibing Yan, Ilsung Chang, Anne Uyei, Louise Roberts, Fortunato Ciardiello, JB Ahn, Jamil Asselah, Suprith Badarinath, Shobhit Baijal, S. Begbie, Sneha Berry, J. R. Canon, RG Carbone, Andrés Cervantes, YJ Cha, Karen Chang, Arvind Chaudhry, Ewa Chmielowska, Seung‐Hun Cho, Derek K. Chu, Félix Couture, Jennifer L. Cultrera, David Cunningham, Eric Van Cutsem, P-J. Cuyle, Janine M. Davies, Scot Dowden, Mikhail Dvorkin, Vinod Ganju, RV Garcia, Rachel Kerr, Tae‐Yop Kim, Kevin G. King, Jeremy Kortmansky, Mark Kozloff, Ko Lam, J Lee, AS Lee, Bernard Lespérance, Gabriele Luppi, Boyu Ma, Evaristo Maiello, Romeo A. Mandanas, J. L. Marshall, Gavin Marx, Saifee Mullamitha, Marina Nechaeva, Jo Park, Nick Pavlakis, CG Ponce, Piotr Potemski, Sherif Raouf, James A. Reeves, Neil H. Segal, Salvatore Siena, Alexey Smolin, JO Streb, A. H. Strickland, Ewa Szutowicz-Zielińska, Josep Tabernero, Benjamin Tan, JS Valera, Marc Van den Eynde, Philippe Vergauwe, Michael M. Vickers, Mark Womack, Marta Wróblewska, Ruth T. Young - The Lancet Oncology 2019 cited by 562

  11. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

    Authors: Jayesh Desai, Guzmán Alonso, Se Hyun Kim, Andrés Cervantes, Thomas B. Karasic, Laura Medina, Einat Shacham‐Shmueli, Rasha Cosman, Alejandro Falcón, Eelke Gort, Tormod Kyrre Guren, Erminia Massarelli, Wilson H. Miller, Luis Paz‐Ares, Hans Prenen, Alessio Amatu, Chiara Cremolini, Tae Won Kim, Víctor Moreno, Sai‐Hong Ignatius Ou, Alessandro Passardi, Adrian G. Sacher, Armando Santoro, Rafał Stec, Susanna V. Ulahannan, Kathryn C. Arbour, Patricia LoRusso, Jia Luo, Manish R. Patel, Yoonha Choi, Zhen Shi, Sandhya Mandlekar, Mark T. Lin, Stephanie Royer‐Joo, Julie Chang, Tomi Jun, Neekesh V. Dharia, Jennifer L. Schutzman, GO42144 Investigator and Study Group, Sae-Won Han - Nature Medicine 2023 cited by 122

  12. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

    Authors: Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn, Radka Obermannová, G. Bodoky, Rocio García‐Carbonero, Tudor–Eliade Ciuleanu, David C. Portnoy, Eric Van Cutsem, Axel Grothey, Jana Prausová, Pilar García‐Alfonso, Kentaro Yamazaki, Philip R. Clingan, Sara Lonardi, Tae Won Kim, Lorinda Simms, Shao-Chun Chang, Federico Nasroulah - The Lancet Oncology 2015 cited by 955

  13. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Jin Li, Shukui Qin, Rui‐Hua Xu, Thomas Yau, Brigette Ma, Hongming Pan, Jianming Xu, Yuxian Bai, Yihebali Chi, Liwei Wang, Kun‐Huei Yeh, Feng Bi, Ying Cheng, Anh T. Le, Jen-Kou Lin, Tianshu Liu, Dong Ma, Christian Kappeler, J. Kalmus, Tae Won Kim - The Lancet Oncology 2015 cited by 816

  14. The Impact of Sleep and Circadian Disturbance on Hormones and Metabolism

    Authors: Tae‐Won Kim, Jong‐Hyun Jeong, Seung-Chul Hong - International Journal of Endocrinology 2015 cited by 349

  15. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors

    Authors: Tae Won Kim, Philippe L. Bédard, Patricia LoRusso, Michael S. Gordon, Johanna C. Bendell, Do‐Youn Oh, Myung‐Ju Ahn, Elena Garralda, Sandra P. D’Angelo, Jayesh Desai, F. Stephen Hodi, Zev A. Wainberg, Jean‐Pierre Delord, Phillippe A. Cassier, Andrés Cervantes, Marta Gil-Martín, Benjamin Wu, Namrata S. Patil, Yanling Jin, Tien Hoang, Diana Mendus, Xiaohui Wen, Raymond D. Meng, Byoung Chul Cho - JAMA Oncology 2023 cited by 63

  16. ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

    Authors: Ivana Yen, Frances Shanahan, Jeeyun Lee, Yong Sang Hong, Sang Joon Shin, Amanda R. Moore, Jawahar Sudhamsu, Matthew T. Chang, InHwan Bae, Darlene Dela Cruz, Thomas Hunsaker, Christiaan Klijn, Nicholas P. D. Liau, Eva Lin, Scott E. Martin, Zora Modrušan, Robert Piskol, Ehud Segal, Avinashnarayan Venkatanarayan, Xin Ye, Jianping Yin, Liangxuan Zhang, Jin-Soo Kim, Hyeong-Seok Lim, Kyu-pyo Kim, Yu Jung Kim, Hye Sook Han, Soo Jung Lee, Seung Tae Kim, Minkyu Jung, Yoon-Hee Hong, Young Su Noh, Munjeong Choi, Oakpil Han, Małgorzata Nowicka, Shrividhya Srinivasan, Yibing Yan, Tae Won Kim, Shiva Malek - Nature 2021 cited by 135

  17. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial

    Authors: Thierry André, Mayur M. Amonkar, Josephine M. Norquist, Kai-Keen Shiu, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J.A. Punt, Denis Smith, Rocio García‐Carbonero, Isabel Sevilla, Christelle de la Fouchardière, Fernando Rivera, Élena Elez, Luis A. Díaz, Takayuki Yoshino, Eric Van Cutsem, Ping Yang, Mohammed Z.H. Farooqui, Dung T. Le - The Lancet Oncology 2021 cited by 220

  18. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

    Authors: Timothy Price, Marc Peeters, Tae Won Kim, Jin Li, Stefano Cascinu, Paul Ruff, Atilli Satya Suresh, Anne Thomas, Sergei Tjulandin, Kathy Zhang, Swaminathan Murugappan, Roger Sidhu - The Lancet Oncology 2014 cited by 470

  19. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

    Authors: Akihito Kawazoe, Rui‐Hua Xu, Pilar García‐Alfonso, Maria Passhak, Hao‐Wei Teng, Ardaman Shergill, Mahmut Gümüş, Camilla Qvortrup, Sebastian Stintzing, Kathryn Towns, Tae Won Kim, Kai‐Keen Shiu, Juan Cundom, Sumitra Ananda, A. A. Lebedinets, Rong Fu, Rishi Jain, David E. Adelberg, Volker Heinemann, Takayuki Yoshino, Elena Élez, the LEAP-017 Investigators, Juan Cundom, Ezequiel Slutsky, Julieta Grasselli, Luis Fein, Luciana Bella Quero, Warren Joubert, Peter Gibbs, Timothy Price, Matthew Burge, Sumitra Ananda, Muhammad A. Khattak, Bruce Colwell, Félix Couture, Brandon M. Meyers, Kathryn Towns, Michael B. Sawyer, Lucas Sidéris, Rui‐Hua Xu, Wei Wang, Hongming Pan, Per Pfeiffer, Lars Henrik Jensen, Camilla Qvortrup, Sebastian Stintzing, Dirk Arnold, Sylvie Lorenzen, Stefan Kubicka, Reinhard Depenbusch, Maria Passhak, Ravit Geva, Ayala Hubert, Einat Shacham‐Shmueli, Gleb Kornev, Akihito Kawazoe, Toshiki Masuishi, Atsuo Takashima, Hiroki Hara, Hisato Kawakami, Nozomu Machida, Kentaro Yamazaki, Hisateru Yasui, Akihito Tsuji, Taito Esaki, Kensei Yamaguchi, Tae‐You Kim, Joong Bae Ahn, Myung Ah Lee, Tae Won Kim, Joon Oh Park, Soo Hyun Lee, Р. В. Орлова, V. O. Sarzhevskiy, Marina Sekacheva, S. Tjulandin, Oksana Shirokova, A.I. Iskhakova Iskhakova, A. A. Lebedinets, Paula Jiménez Fonseca, F. Rivera Herrero, Elena Elez Fernandez, Pilar Alfonso, M.J. Gómez Reina, Kun‐Huei Yeh, Hao‐Wei Teng, Tsai Sheng Yang, Hwei‐Ming Wang, Yu‐Min Yeh, Mustafa Özgüroğlu, Mahmut Gumus, Şuayib Yalçın, Bülent Erdoğan, Umut Demırcı, Pınar Gürsoy, Hakan Harputluoğlu, Atakan Demir, Kai‐Keen Shiu, Ewan Brown, Paul J. Ross and 13 more - Journal of Clinical Oncology 2024 cited by 77

  20. Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164

    Authors: Dung T. Le, Luis A. Díaz, Tae Won Kim, Eric Van Cutsem, Ravit Geva, Dirk Jäger, Hiroki Hara, Matthew Burge, Bert H. O’Neil, Petr Kavan, Takayuki Yoshino, Rosine Guimbaud, Hiroya Taniguchi, Elena Élez, Salah-Eddin Al-Batran, Patrick M. Boland, Yi Cui, Pierre Leconte, Patricia Marinello, Thierry André - European Journal of Cancer 2023 cited by 93

  21. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study

    Authors: Jianming Xu, Tae Won Kim, Lin Shen, Virote Sriuranpong, Hongming Pan, Rui‐Hua Xu, Weijian Guo, Sae‐Won Han, Tianshu Liu, Young Suk Park, Chunmei Shi, Yuxian Bai, Feng Bi, Joong Bae Ahn, Shukui Qin, Qi Li, Changping Wu, Dong Ma, Donghu Lin, Jin Li - Journal of Clinical Oncology 2017 cited by 257

  22. Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial

    Authors: Hyung‐Don Kim, Seyoung Jung, Ho Yeong Lim, Baek‐Yeol Ryoo, Min‐Hee Ryu, Samuel Chuah, Hong Jae Chon, Beodeul Kang, Jung Yong Hong, Han Chu Lee, Deok‐Bog Moon, Ki‐Hun Kim, Tae Won Kim, David Tai, Valerie Chew, Jeong Seok Lee, Richard S. Finn, June‐Young Koh, Changhoon Yoo - Nature Medicine 2024 cited by 67

  23. Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer

    Authors: Lucia Taraborrelli, Yasin Şenbabaoğlu, Lifen Wang, Junghyun Lim, Kerrigan Blake, Noelyn M. Kljavin, Sarah Gierke, Alexis Scherl, James Ziai, Erin McNamara, Mark Owyong, Shilpa C. Rao, Aslıhan Karabacak Calviello, Daniel Oreper, Suchit Jhunjhunwala, Guillem Argilés, Johanna C. Bendell, Tae Won Kim, Fortunato Ciardiello, Matthew Wongchenko, Frédéric J. de Sauvage, Felipe de Sousa e Melo, Yibing Yan, Nathaniel R. West, Aditya Murthy - Nature Communications 2023 cited by 38

  24. Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial

    Authors: Scott Kopetz, Takayuki Yoshino, Eric Van Cutsem, Cathy Eng, Tae Won Kim, Harpreet Wasan, Jayesh Desai, Fortunato Ciardiello, Rona Yaeger, Tim Maughan, Elena Beyzarov, Xiaoxi Zhang, Graham Ferrier, Xiaosong Zhang, Josep Tabernero - Nature Medicine 2025 cited by 101